Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Estrogens, conjugated (USP) / medroxyprogesterone price, strengths & recalls

Pharmacies pay $8.68 for 1 kit of Estrogens, conjugated (USP) / medroxyprogesterone 28 day pack this week, and from $8.68 to $243.41 across its 5 priced strengths and forms. Its official label last changed on April 29, 2026.

Generic
Pharmacies pay$8.68for 1 kit of 28 day packNo change in 4 weeks
Fair cash price
$20.48
Strengths
5
Makers
1
Updated
Nov 11

Estrogens, conjugated (USP) / medroxyprogesterone price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
0.3/1.5 28 day pack$8.68$243.02 / 28 tabletsNo change+2.7%
0.45/1.5 28 day pack$8.69$243.41 / 28 tablets+0.1%+2.7%
0.625/2.5 28 day pack$8.68$242.91 / 28 tabletsNo change+2.6%
0.625/5 28 day pack$8.67$242.66 / 28 tabletsNo change+2.4%
28 day pack$8.68$8.68 / 1 kitNo change+2.7%

The lowest cost per tablet is 0.625/5 28 day pack at $8.67. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Supply status: shortages & recalls

No shortage reportedChecked Nov 17, 2026
No ongoing recallsNone on record

What did you pay for estrogens, conjugated (usp) / medroxyprogesterone? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedApril 29, 2026
Version39 of 26
EffectiveApr 28, 2026
Read the label

These highlights do not include all the information needed to use PREMPRO/PREMPHASE safely and effectively. See full prescribing information for PREMPRO/PREMPHASE.PREMPRO® (conjugated estrogens/medroxyprogesterone acetate tablets) PREMPHASE® (conjugated estrogens plus medroxyprogesterone acetate tablets)Initial U.S. Approval: 1995

This drug has a boxed warning

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA

Estrogen Plus Progestin Therapy

Cardiovascular Disorders and Probable Dementia

Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.6, 14.7)].

The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg), relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.6)].

The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.7)].

Breast Cancer

The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2), and Clinical Studies (14.6)].

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Estrogen-Alone Therapy

Endometrial Cancer

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2)].

Cardiovascular Disorders and Probable Dementia

Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.6, 14.7)].

The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.6)].

The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.7)].

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA

See full prescribing information for complete boxed warning.

Estrogen Plus Progestin Therapy

•

Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3)

•

The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI) (5.1)

•

The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (5.2)

•

The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)

Estrogen-Alone Therapy

•

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (5.2)

•

Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3)

•

The WHI estrogen-alone substudy reported increased risks of stroke and DVT (5.1)

•

The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA020527 · Wyeth Pharms
First approved
November 17, 1995 (31 years ago)
Latest approved change
April 22, 2025
Approved label
PDF, Apr 24, 2025
Generic makers
None on the market

Estrogens, conjugated (USP) / medroxyprogesterone questions

How much does estrogens, conjugated (usp) / medroxyprogesterone cost without insurance?

Pharmacies pay about $8.68 for 1 kit of estrogens, conjugated (usp) / medroxyprogesterone 28 day pack ($8.68 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $20.48. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is estrogens, conjugated (usp) / medroxyprogesterone in shortage?

No shortage is reported for estrogens, conjugated (usp) / medroxyprogesterone right now. We check the national shortage list every day.

Has estrogens, conjugated (usp) / medroxyprogesterone been recalled?

No recalls are on record for estrogens, conjugated (usp) / medroxyprogesterone.

When did the estrogens, conjugated (usp) / medroxyprogesterone label last change?

The official label was last updated on April 29, 2026 (version 39). See what changed.

Talk about estrogens, conjugated (usp) / medroxyprogesterone

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.